Curetis is a young, dynamic and creative molecular diagnostics company. They are specialized in the diagnosis of severe infectious diseases in hospitalized patients. The company helps to combat infections effectively and detect antibiotic resistance at an early stage.
New investors Qiagen and LSP Health Economics Fund (LSP-HEF) participated in the round with a commitment of €7 million, joining several existing investors that together committed €7.5 million. The existing investors included Aeris Capital, BioMed Invest, CD Venture, Forbion Capital, HBM Partners, Life Science Partners, Roche Venture Fund, Curetis management, a trustee pool of Curetis employees, and private angel investors.
The European market introduction of both the Unyvero P50 Pneumonia and i60 Implant and Tissue Infection applications, allowing a faster and better diagnosis of life-threatening infectious diseases, has shown increasing traction.